Analyst Activity – Deutsche Bank AG Reiterates Buy on Bio-Rad Laboratories (NYSE:BIO)

Analyst Ratings For Bio-Rad Laboratories (NYSE:BIO)

Story continues below

Today, Deutsche Bank AG reiterated its Buy rating on Bio-Rad Laboratories (NYSE:BIO) with a price target of $255.00.

There are 4 buy ratings on the stock.

The current consensus rating on Bio-Rad Laboratories (NYSE:BIO) is Buy (Score: 3.00) with a consensus target price of $240.00 per share, a potential 4.53% upside.

Some recent analyst ratings include

  • 9/18/2017-Deutsche Bank AG Reiterated Rating of Buy.
  • 7/14/2017-Jefferies Group LLC Reiterated Rating of Buy.
  • 7/13/2017-Wells Fargo & Company initiated coverage with a Outperform rating.
  • 10/12/2016-CL King initiated coverage with a Buy rating.

Recent Insider Trading Activity For Bio-Rad Laboratories (NYSE:BIO)
Bio-Rad Laboratories (NYSE:BIO) has insider ownership of 28.29% and institutional ownership of 62.84%.

  • On 8/11/2017 Michael Crowley, EVP, sold 700 with an average share price of $215.91 per share and the total transaction amounting to $151,137.00. View SEC Filing
  • On 3/7/2017 Michael Crowley, EVP, sold 300 with an average share price of $196.13 per share and the total transaction amounting to $58,839.00. View SEC Filing
  • On 11/9/2016 James R. Stark, VP, sold 1,299 with an average share price of $171.42 per share and the total transaction amounting to $222,674.58. View SEC Filing

Recent Trading Activity for Bio-Rad Laboratories (NYSE:BIO)
Shares of Bio-Rad Laboratories closed the previous trading session at with shares trading hands.

An ad to help with our costs